SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-339720"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-339720" > Understanding the P...

Understanding the Patient Experience with Carcinoid Syndrome : Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Anthony, Lowell (författare)
Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
Ervin, Claire (författare)
RTI Hlth Solut, Res Triangle Pk, NC USA.
Lapuerta, Pablo (författare)
Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
visa fler...
Kulke, Matthew H. (författare)
Dana Farber Canc Inst, Boston, MA 02115 USA.
Kunz, Pamela (författare)
Stanford Canc Ctr, Stanford, CA USA.
Bergsland, Emily (författare)
UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Hörsch, Dieter (författare)
Zent Klin Bad Berka GmbH, Klin Innerre Med Gastroenterol & Endokrinol, Bad Berka, Germany.
Metz, David C. (författare)
Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
Pasieka, Janice (författare)
Tom Baker Canc Clin, Calgary, AB, Canada.
Paylakis, Nick (författare)
Royal North Shore Hosp, St Leonards, NSW, Australia.
Pavel, Marianne (författare)
Charite, Berlin, Germany.
Caplin, Martyn (författare)
Royal Free Hosp, London, England.
Öberg, Kjell, 1946- (författare)
Uppsala universitet,Endokrin tumörbiologi
Ramage, John (författare)
Hampshire Hosp NHS Trust, Basingstoke & North Hampshire Hosp, Basingstoke, Hants, England.
Evans, Emily (författare)
RTI Hlth Solut, Res Triangle Pk, NC USA.
Yang, Qi Melissa (författare)
Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
Jackson, Shanna (författare)
Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
Arnold, Katie (författare)
Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.
Law, Linda (författare)
Lexicon Pharmaceut Inc, 8800 Technol Forest Pl, The Woodlands, TX 77385 USA.;BioHealthConsult, 2143 Riverside Dr, Cincinnati, OH 45202 USA.
DiBenedetti, Dana B. (författare)
RTI Hlth Solut, Res Triangle Pk, NC USA.
visa färre...
Univ Kentucky, Markey Canc Ctr, Lexington, KY USA RTI Hlth Solut, Res Triangle Pk, NC USA. (creator_code:org_t)
Elsevier, 2017
2017
Engelska.
Ingår i: Clinical Therapeutics. - : Elsevier. - 0149-2918 .- 1879-114X. ; 39:11, s. 2158-2168
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose: Telotristat ethyl, an oral tryptophan hydroxylase inhibitor, is intended to treat carcinoid syndrome by reducing serotonin production. Telotristat ethyl was evaluated in FELESTAR, a Phase HI study for patients who had carcinoid syndrome with at least 4 bowel movements (BMs) per day and who were receiving somatostatin analogue therapy. This interview sub study was conducted to provide insight into the patient experience in ILLESTAR and to help understand whether reductions in BM frequency (the primary end point) and other symptoms were clinically meaningful. Methods: Participating sites were asked to invite (before randomization) all eligible patients to telephone interviews scheduled at the end of the double-blind treatment period. Patients and interviewers were blinded to treatment. Findings: All 35 interviewed participants reported diarrhea and/or excessive BMs at baseline. Patients reported that these symptoms negatively affected emotional, social, physical, and occupational well-being. Prespecified criteria for treatment response (achieving >= 30% reduction in BM frequency for at least 50% of the days) were met by 8 of 26 patients taking telotristat ethyl and 1 of 9 patients taking placebo. All 8 patients taking telotristat ethyl described clinically meaningful reductions in BM frequency and were very satisfied with the ability of the study drug to control their carcinoidsyndrome symptoms. Overall, reports of being very satisfied were observed in 12 patients taking telotristat ethyl and 0 taking placebo. Implications: Patient interviews revealed that I ELESTAR patients, at baseline, were significantly affected by their high BM frequency. Patient reports of their clinical trial experience supported the significance of the primary end point and clinical responder analysis in TELESTAR, helping identify and understand clinically meaningful change produced by telotristat ethyl. (C) 2017 The Authors. Published by Elsevier HS Journals, Inc.

Ämnesord

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Social and Clinical Pharmacy (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Samhällsfarmaci och klinisk farmaci (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine (hsv//eng)

Nyckelord

bowel movement
carcinoid syndrome
diarrhea
exit interviews
patient interviews
telotristat ethyl

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy